Melissa Alsina

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 740 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 655 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

Paul G. Richardson, Hannah Briemberg, Sundar Jagannath et al. · Journal of Clinical Oncology · 2006 · 650 citations · Full text

Medicine, Neurology, Pharmacotherapy +17